NCT04493138 2026-05-04Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL MutationsM.D. Anderson Cancer CenterPhase 1/2 Active not recruiting30 enrolled